Showing results (171-180 of 199) with videos related to

Sort By:
Pageof 20
ESMO Open|November 18, 2025
Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50A De Giglio, L Zullo, A Di Federico, et al.
Molecular Cancer|November 13, 2024
The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancerW J McDaid, L Wilson, H Adderley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 20, 2021
Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistanceY Loriot, A Marabelle, J P Guégan, et al.
ESMO Open|December 25, 2021
IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancerO Molinier, B Besse, F Barlesi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2017
Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) programC Leduc, J P Merlio, B Besse, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trialB Besse, J Mazières, L Ribassin-Majed, et al.
Clinical Lung Cancer|March 19, 2021
RADIORYTHMIC: Phase III, Opened, Randomized Study of Postoperative Radiotherapy Versus Surveillance in Stage IIb/III of Masaoka Koga Thymoma after Complete Surgical ResectionC Basse, A Botticella, T J Molina, et al.
ESMO Open|March 1, 2022
Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU studyN Girard, S Galland-Girodet, V Avrillon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 2, 2023
Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trialJ Remon, B Besse, S Ponce Aix, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 23, 2022
Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patientsJ Chen, F Facchinetti, F Braye, et al.
Pageof 20